GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
GO:003424914 | Esophagus | ESCC | negative regulation of cellular amide metabolic process | 144/8552 | 273/18723 | 1.08e-02 | 3.67e-02 | 144 |
GO:000218120 | Oral cavity | OSCC | cytoplasmic translation | 133/7305 | 148/18723 | 1.94e-38 | 2.46e-35 | 133 |
GO:000641720 | Oral cavity | OSCC | regulation of translation | 274/7305 | 468/18723 | 4.39e-18 | 4.63e-16 | 274 |
GO:000170116 | Oral cavity | OSCC | in utero embryonic development | 207/7305 | 367/18723 | 7.92e-12 | 2.95e-10 | 207 |
GO:00342495 | Oral cavity | OSCC | negative regulation of cellular amide metabolic process | 130/7305 | 273/18723 | 2.20e-03 | 1.00e-02 | 130 |
GO:00171485 | Oral cavity | OSCC | negative regulation of translation | 113/7305 | 245/18723 | 1.34e-02 | 4.45e-02 | 113 |
GO:0002181110 | Oral cavity | LP | cytoplasmic translation | 124/4623 | 148/18723 | 5.09e-52 | 3.19e-48 | 124 |
GO:0006417110 | Oral cavity | LP | regulation of translation | 175/4623 | 468/18723 | 4.49e-10 | 2.22e-08 | 175 |
GO:000170117 | Oral cavity | LP | in utero embryonic development | 142/4623 | 367/18723 | 1.48e-09 | 6.75e-08 | 142 |
GO:000218126 | Oral cavity | EOLP | cytoplasmic translation | 102/2218 | 148/18723 | 7.91e-60 | 4.74e-56 | 102 |
GO:000641726 | Oral cavity | EOLP | regulation of translation | 108/2218 | 468/18723 | 4.04e-12 | 7.34e-10 | 108 |
GO:001714813 | Oral cavity | EOLP | negative regulation of translation | 54/2218 | 245/18723 | 4.15e-06 | 8.72e-05 | 54 |
GO:003424913 | Oral cavity | EOLP | negative regulation of cellular amide metabolic process | 58/2218 | 273/18723 | 6.23e-06 | 1.22e-04 | 58 |
GO:000170123 | Oral cavity | EOLP | in utero embryonic development | 72/2218 | 367/18723 | 1.02e-05 | 1.83e-04 | 72 |
GO:20007653 | Oral cavity | EOLP | regulation of cytoplasmic translation | 7/2218 | 16/18723 | 1.40e-03 | 9.58e-03 | 7 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UNK | SNV | Missense_Mutation | novel | c.2419N>C | p.Thr807Pro | p.T807P | Q9C0B0 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
UNK | SNV | Missense_Mutation | novel | c.122N>T | p.Arg41Leu | p.R41L | Q9C0B0 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
UNK | SNV | Missense_Mutation | | c.350N>C | p.Glu117Ala | p.E117A | Q9C0B0 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
UNK | SNV | Missense_Mutation | rs752774700 | c.1966N>A | p.Glu656Lys | p.E656K | Q9C0B0 | protein_coding | deleterious(0.03) | probably_damaging(0.956) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
UNK | SNV | Missense_Mutation | novel | c.877N>T | p.Ile293Phe | p.I293F | Q9C0B0 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-LD-A7W6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | letrozole | SD |
UNK | insertion | Frame_Shift_Ins | novel | c.702_703insC | p.Tyr236LeufsTer30 | p.Y236Lfs*30 | Q9C0B0 | protein_coding | | | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UNK | deletion | Frame_Shift_Del | | c.1451delN | p.Pro486LeufsTer12 | p.P486Lfs*12 | Q9C0B0 | protein_coding | | | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UNK | deletion | Frame_Shift_Del | novel | c.1523delN | p.Ser508ThrfsTer4 | p.S508Tfs*4 | Q9C0B0 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
UNK | SNV | Missense_Mutation | novel | c.1082N>T | p.Pro361Leu | p.P361L | Q9C0B0 | protein_coding | tolerated(0.15) | probably_damaging(0.982) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
UNK | SNV | Missense_Mutation | | c.2143N>A | p.Glu715Lys | p.E715K | Q9C0B0 | protein_coding | tolerated(0.17) | benign(0.431) | TCGA-C5-A1BN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |